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A B S T R A C T
The effect of punicalagin on metabolic risks, oxidative stress, inflammation, cardiac apopto-
sis and histopathological alterations in experimentally induced diabetes was addressed.Diabetes
was induced in male rats by a single injection of streptozotocin (STZ; 40 mg/kg, i.p.), and then
punicalagin (1mg/kg) was i.p. administered every other day for 15 days.The diabetic rats treated
with punicalagin exhibited ameliorated hyperglycemia and HbA1c; improved insulin levels,
HOMA-IR levels and lipid profiles; and normalized levels of IL-1b, IL-6 andTNF-α. Punicalagin
also reduced the increase in the MDA and H2O2 levels; normalized the levels of GSH, SOD and
CAT in the heart; and improved serum markers of heart function including the levels of tro-
poninT level and CK-MB and LDH activities. Histopathological examinations of heart sections
match these results, confirming the beneficial effect of punicalagin. It also modulated
cardiomyocyte apoptosis via enhanced Bcl-2 expression; blocked the increases in P53, Bax and
caspases-3, 8 and 9; and ameliorated DNA damage in the heart. The current results suggest
that punicalagin protected the heart against apoptosis, necrosis, inflammation and DNA damage
by improving the redox state, suppressing caspases and P53 and increasing Bcl-2. In conclu-
sion, punicalagin possesses strong therapeutic potential in treating and regulating diabetes
and attenuating its associated complications in the heart.
© 2015 Mansoura University. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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1. Introduction
The prevalence of the diabetic heart has markedly increased in
the past few years and is now considered themain cause of sick-
ness and death among the diabetic and obese population.
Diabetic cardiomyopathy is associated with increased oxida-
tive stress that stimulates cellular injury and contributes to the
development and progression of complications associated with
diabetes [1]. Apoptosis is a key process in diabetic cardiac dis-
eases derived from poor glycemic control. A number of studies
have documented an increased occurrence of apoptosis in the
cardiomyocytes of diabetic patients and experimentally induced
diabetic animals [2,3]. It is mediated, at least in part, by the ac-
tivation of the mitochondrial pathway, which is often triggered
by reactive oxygen species (ROS).
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There is evidence from experimental and clinical settings on
the benefits of antioxidant therapies in the prevention andman-
agement of diabetic complications [4–6]. Pomegranate (Punica
granatum L. Punicaceae) juice has been shown to contain the
highest antioxidant capacity compared to other polyphenol-
rich beverages [7,8]. Clinical studies showed positive effects of
pomegranate juice consumption on diabetic patients’ blood dia-
betic and oxidative stress parameters [9]. Furthermore, it is
documented that pomegranate juice supplementation showed
a protective effect against isoperiotinaol-induced cardiac ne-
crosis in rats [10]. The efficient antioxidant potential of the
pomegranate is attributed to its major antioxidant polyphenol,
punicalagin [11]. A primary mechanism by which pomegran-
ate fractions exert their beneficial effects on the disease condition
is by reducing oxidative stress and lipid peroxidation. This re-
duction may occur by directly neutralizing the generated ROS,
enhancing the activities of specific antioxidant enzymes, prompt-
ing metal chelation activity, and inhibiting or activating certain
transcriptional factors, such as nuclear factor kappaB and per-
oxisome proliferator-activated receptor gamma [12].
Punicalagin is a bioactive ellagitannin, a type of phenolic
compound isolated from pomegranate and exhibits high an-
tioxidant and free radical scavenging activities [13], with several
health benefits [14]. It demonstrated a marked outcome in pa-
tients with metabolic syndromes, such as hyperlipidemia, non-
alcoholic fatty liver disease, and coronary heart disease
[12,15–17]. Punicalagin inhibits the formation of advanced
glycation end-products [18] and fructose-mediated non-
enzymatic protein glycation by scavenging reactive carbonyl
species [19]. Good results in terms of fat loss [20] and inhibi-
tion of oxidized LDL uptake in macrophages [21] have been
demonstrated using punicalagin. In addition to its antioxi-
dant, anti-diabetic and anti-atherosclerotic actions [12,14],
punicalagin also exhibited anti-inflammatory activity in cell
culture and animal studies [22,23]. It is worth mentioning that
repeated oral administration with punicalagin for five weeks
is not toxic to rats [24].
Because diabetes is associated with high frequency of heart
failure, a better understanding of its pathophysiology is es-
sential for testing of new bioactive compounds and the
development of treatment strategies for diabetes-associated
cardiac dysfunction. To date, no studies regarding the effect
of punicalagin on diabetic cardiac apoptosis and injury have
been conducted. The present study hypothesized that
punicalagin can counteract oxidative stress and, in turn, ame-
liorate cellular damage and reduce the development and
progression of diabetic complications. Therefore, the current
study was designed to investigate the potential beneficial effect
of punicalagin against diabetes-induced cardiac injury and
apoptosis in connection with its anti-lipid peroxidation and
anti-hyperlipidemic actions.
2. Materials and methods
2.1. Chemicals
Streptozotocin (STZ) and punicalagin (PU) were purchased from
Sigma Chemical (St. Louis, MO). All other chemicals were of
the highest grade.
2.2. Induction of diabetes
Diabetes was induced in rats by single intraperitoneal (i.p.) in-
jections of freshly prepared STZ (40 mg/kg body weight) in
0.01 M citrate buffer, pH 4.5 [25]. The blood glucose level was
assayed 48 h after STZ injection using a glucose monitor set
(Elegance, CT-X10, Convergent Technologies GmbH & Co. KG,
Marburg, Germany). The rats with a blood glucose level above
250 mg/dl were considered diabetic and were used for the
experiments.
2.3. Punicalagin treatment
Punicalagin is supplied in water soluble dark-yellow powder.
Applied dose of 1 mg/kg dissolved in 0.2 ml saline solution was
daily i.p. administered for 15 days [26].
2.4. Experimental work
MaleWister rats weighing 280–300 g were provided by the Bio-
logical Products &Vaccines (VACSERA) of Cairo, Egypt, and were
housed in cages with free access to food and drinking water.
The animals were acclimated to laboratory conditions of 22–
24 °C with a 12-h light/dark cycle for two weeks before
experimentation.The current study was approved by Mansoura
University, and all experiments were performed in accor-
dance with the standards accepted by the regional experimental
animal ethics panel. The rats were divided randomly into four
groups of seven rats each. The first group served as a control,
the second group received a daily dose of punicalagin (1 mg/kg,
i.p.) for 15 days, the third group received a single i.p. injec-
tion of 40 mg/kg STZ, and the fourth group received a single
injection of STZ (40mg/kg, i.p.) followed by punicalagin (1mg/kg,
i.p.) every other day for two weeks. After 15 days of treat-
ment, blood was obtained by cardiac puncture after overnight
fasting. Serum and heart ventricle were kept in refrigerator for
the following investigations.
2.5. Biochemical investigations
The glucose and insulin levels in serum and the HbA1c levels
in blood were determined using kits supplied by Spinreact (St.
Esteve d’en Bas Girona, Spain), Abcam (Cambridge, MA, USA)
and BioSystems (Barcelona, Spain), respectively. The lipid pro-
files in serum, including total lipids, triglyceride, total
cholesterol, high-density lipoprotein (HDL), low-density lipo-
protein (LDL) and very low-density lipoproteins (VLDL), were
assayed according to themanufacturer’s instructions (Spinreact,
St. Esteve d’en Bas Girona, Spain). Interleukin 6 (IL-6), interleukin
1 beta (IL-1b), tumor necrosis factor alpha (TNF-α) and tropo-
nin T in serum were assessed using kits provided by R&D
Systems (Minneapolis, MN, USA) and Bioscience (San Diego, CA,
USA). Creatine kinase (CK-MB) and lactic dehydrogenase (LDH)
activities in the serum were determined using kits pur-
chased from Elitech (Puteaux, France). Lipid peroxidation was
assessed by determining the amount of malondialdehyde
(MDA). The hydrogen peroxide (H2O2) concentrations were es-
timated according to the manufacturer’s instructions (Dokki-
Giza, Egypt).The superoxide dismutase (SOD) and catalase (CAT)
activities and the glutathione (GSH) concentration were assayed
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using kits provided by Biodiagnostic (Dokki-Giza, Egypt). The
protein concentrations were assayed as previously described
[27].
2.6. Flow cytometry study
2.6.1. Determination of apoptosis
For flow cytometry, samples from the heart were prepared as
previously described [28].The cells were suspended in PBS with
BSA, divided into aliquots and stored at 4 °C for analysis. The
flow cytometry analyses were performed on a FACSCalibur™
cytometer (BD Biosciences, San Jose, CA) using CellQuest Pro
software (Becton Dickinson) for data acquisition and analysis
[29].
2.6.2. Annexin V/PI staining
Apoptosis was assessed using the fluorescein isothiocyanate-
conjugated annexinV/PI, ApoAlert kit from Clontech (Palo Alto,
CA) according to the manufacturer’s instructions.
2.6.3. Bcl-2, Bax, P53 and CD95
The cell suspensions were prepared in a PBS/BSA buffer and
were then incubated for 30 min with anti-Bcl-2 [100/D5] anti-
body (ab692) and anti-Bax [6A7] antibody (ab5714) for flow
cytometry analysis of Bcl-2 and Bax, respectively.A mouse anti-
P53 “aa20-25” FITC, Clone: DO-1, was used for P53 analysis by
flow cytometry. A monoclonal anti-Fas (CD95/Apo-1) anti-
body was used for CD95 determination.After 30-min incubation
at room temperature, the cells were washed with PBA/BSA,
centrifuged at 400 × g for 5 min, re-suspended in 0.5% paraform-
aldehyde in PBS/BSA and analyzed using flow cytometry.
2.6.4. Caspases-3, -8 & -9
In case of caspases-3, -8 and - 9: FITC rabbit anti-active
caspase-3 (CPP32;Yama; Apopain, BD Bioscience), anti-caspase-8
(E6) antibody (Abcam) or rabbit monoclonal anti-caspase-9 (E23)
antibody (ab32539) were used respectively.
2.7. Single cell gel electrophoresis (Comet assay)
DNA damage in the heart samples was assessed using the
single-cell gel electrophoresis (comet assay) method, a
well-validated technique developed for measuring DNA strand
breaks in individual cells, as described previously [30,31]. The
quantification of the DNA strand breaks in the obtained images
was performed with CASP software to directly obtain the
percent of DNA in the tail, the tail length and the tail moment.
2.8. Histopathological examination
The ventricle was excised and fixed in 4% buffered paraform-
aldehyde, dehydrated in ascending grades of ethyl alcohol,
cleared in xylene and mounted in molten paraplast 58–62C.
Four micron histological section were cut, stained with he-
matoxylin and eosin and examined under bright field light
microscopy and photographed.
2.9. Statistical analysis
The data were presented as the mean ± SEM. The statistical
analyses were performed by one-way ANOVA followed by Stu-
dents Newman–Keul’s post hoc test.
3. Results
The administration of punicalagin alone every other day for
two weeks did not affect the body weight, the concentration
of glucose, insulin or the lipid profile. Similarly, punicalagin
treatment did not affect the levels of IL-1b and IL-6. Further-
more, the activities of SOD and CAT and the lipid peroxidation
product (TBARS) in the heart did not change after punicalagin
treatment. Conversely, significant increases were demon-
strated in the HDL level in the serum and the GSH level in the
heart.
3.1. Body weight
The body weight of the STZ-treated rats significantly and gradu-
ally decreased compared to that of the normal rats.The diabetic
rats treated with punicalagin (1 mg/kg; every other day) showed
a significant increase in body weight during the experimen-
tal period compared with the diabetic group (Fig. 1a); however,
they remained significantly lower than the control group.
3.2. Blood sugar, insulin and HbA-1c levels
The blood glucose of the diabetic rats was significantly in-
creased during the experimental period compared to that of
the control group. The diabetic rats treated with punicalagin
exhibited a marked amelioration over the experimental period
(Fig. 1b) and at the end of the experimental period (Table 1)
compared with the diabetic group, but the level was signifi-
cantly lower than that of the control group.
The STZ injection significantly elevated the serum glucose
and HbA-1c levels two weeks after diabetic induction (Table 1).
In addition these rats had significantly lower insulin levels and
higher HOMA-IR than the controls (Table 1). Punicalagin treat-
ment for 15 days after diabetic induction significantly
ameliorated the serum glucose and HbA-1c levels compared
to the STZ-treated rats. The diabetic rats treated with
punicalagin exhibited a significant increase in the insulin levels
and a decrease in the HOMA-IR values compared to the dia-
betic rats, but the results were similar to the control levels.
3.3. Biochemical observations
3.3.1. Serum lipid profiles
The lipid profile, including total lipids,TG, total cholesterol, LDL
andVLDL, were significantly higher and HDL was significantly
lower in the STZ-treated rats than in the control rats.
Punicalagin treatment significantly ameliorated these lipid frac-
tions at 15 days after diabetic induction in the rats (Fig. 2).
3.3.2. Serum markers of heart function
The concentration of troponinT and the activity of CK-MB and
LDH in heart were significantly increased in STZ-induced dia-
betes compared to the normal control animals (Table 2).When
diabetic rats were treated with punicalagin, the activity of both
enzymes and troponin T level was normalized to a level com-
parable to that of the control rats and was significantly lower
than that of the diabetic animals.
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3.3.3. Oxidative stress and antioxidants
The levels of the lipid peroxidation product and H2O2 were sig-
nificantly increased in the hearts of the STZ-induced diabetic
rats (Fig. 3). In addition, significant decreases were demon-
strated in the SOD and CAT activities and the GSH content in
the hearts of STZ-treated rats.These changes appeared similar
to control levels when punicalagin was administered for 15 days
after diabetic induction and were significantly better than those
of the diabetic rats (Fig. 3).
3.3.4. Proinflammatory cytokines
The ability of punicalagin to influence the production of IL-
1b, IL-6, TNF-α was measured in the serum of the different rat
groups using enzyme immunoassays. Animals that received
STZ had significantly higher levels of IL-1b, IL-6 andTNF-α com-
pared to the control values (Table 3). Punicalagin administration
after diabetic induction ameliorated the increase in these in-
flammatory proteins in the serum and displayed insignificant
changes when compared to the diabetic rats.
Fig. 1 – Effects of streptozotocin (STZ) and punicalagin (PU) on blood glucose and body weights in rats in different groups
during the experimental period. The values are expressed as the means ± SEM. (n = 7).
Table 1 – Effects of streptozotocin (STZ) and punicalagin (PU) on the serum glucose (mg/dl) and insulin (pg/ml) levels and
the percentages of HbA1c and HOMA-IR in rats in different groups at the end of the experimental period.
Control PU STZ STZ + PU
Glucose 82.1 ± 11.98 104.9 ± 10.71 577.8 ± 18.6*** 115.2 ± 15.4###
Insulin 99.19 ± 3.42 108.7 ± 11.8 38.44 ± 2.14*** 110.7 ± 11.3###
HbA-1c 1.39 ± 0.12 1.13 ± 0.11 5.16 ± 0.19*** 1.66 ± 0.13###
HOMA-IR 20.31 ± 3.45 22.45 ± 2.03 52.53 ± 5.56** 23.7 ± 3.0##
The values are expressed as the means ± SEM. (n = 7). *, # Significant at P < 0.05, **, ## significant at P < 0.01, and ***, ### significant at P < 0.001. *, **,
*** indicate comparisons with respect to the control group. #, ##, ### indicate comparisons with respect to the diabetic group.
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3.4. Flow cytometry of apoptosis and apoptotic proteins
3.4.1. Annexin V/PI
Flow cytometry was used to assess apoptosis in the heart
using Annexin V-FITC staining (Fig. 4). The percentages
of early and late apoptotic cells and necrotic cells were
significantly higher in the hearts of diabetic rats than in
those of the controls. The punicalagin therapy considerably
minimized the number of apoptotic cells compared to the dia-
betic rats.
3.4.2. CD95 and P53
Similarly, CD95 and P53 expressions were significantly in-
creased in the hearts of STZ-treated rats (Fig. 5a,b). Punicalagin
administration after diabetic induction significantly ameliorated
the increase in CD95 and P53 in the heart compared to the
Fig. 2 – Effect of streptozotocin (STZ) and punicalagin (PU) on the lipid profile [total lipids (a), cholesterol (b), triglycerides (c),
low-density lipoprotein (d), high-density lipoprotein (e), and very-low-density lipoprotein (f)] expressed as mg/dl in the
serum in rats in different groups. The values are expressed as the means ± SEM. (n = 7). *, # Significant at P < 0.05, **, ##
significant at P < 0.01, and ***, ### significant at P < 0.001. *, **, *** indicate comparisons with respect to the control group. #, ##,
### indicate comparisons with respect to the diabetic group.
251e g y p t i an j o u rna l o f b a s i c and a p p l i e d s c i e n c e s 2 ( 2 0 1 5 ) 2 4 7 – 2 6 0
Table 2 – Effects of streptozotocin (STZ) and punicalagin
(PU) on the serum troponin T concentration (pg/ml) and
CK-MB and LDH activities (U/ml) rats in different groups.
Control PU STZ STZ + PU
Troponin T 104 ± 7.5 103 ± 4.97 171 ± 9.99*** 99 ± 6.15###
CK-MB 171.6 ± 6.9 143 ± 18.8 396 ± 20.4*** 216 ± 20.5###
LDH 153 ± 10.8 129 ± 36.1 361 ± 14.8*** 194 ± 18.9###
The values are expressed as the means ± SEM. (n = 7). *, # Signifi-
cant at P < 0.05, **, ## significant at P < 0.01, and ***, ### significant at
P < 0.001. *, **, *** indicate comparisons with respect to the control
group. #, ##, ### indicate comparisons with respect to the diabetic group.
Fig. 3 – Effect of streptozotocin (STZ) and punicalagin (PU) on the levels of the lipid peroxidation product MDA (nmol/mg
protein) (a), hydrogen peroxide (H2O2)(mmol/g protein) (b), superoxide dismutase (SOD; U/mg protein) (c), and catalase (CAT;
μmol H2O2/Sec/g protein) (d), glutathione (GSH; mg/g protein) (e) in the hearts of rats in different groups. The values are
expressed as the means ± SEM. (n = 7). *, # Significant at P < 0.05, **, ## significant at P < 0.01, and ***, ### significant at P < 0.001.
*, **, *** indicate comparisons with respect to the control group. #, ##, ### indicate comparisons with respect to the diabetic
group.
Table 3 – Effect of streptozotocin (STZ) and punicalagin
(PU) on the serum IL-6, IL-1b, and TNF-α levels,
expressed as pg/ml, in rats in different groups.
Control PU STZ STZ + PU
IL-6 50.3 ± 2.42 44.2 ± 1.34 72.7 ± 1.98*** 45.9 ± 2.27###
IL-1b 72.9 ± 4.6 61.3 ± 2.72 124.9 ± 4.44*** 75.7 ± 2.09###
TNF-α 35.6 ± 0.81 33.0 ± 1.61 63.8 ± 2.75*** 37.3 ± 0.42*, ###
The values are expressed as the means ± SEM. (n = 7). *, # Signifi-
cant at P < 0.05, **, ## significant at P < 0.01, and ***, ### significant at
P < 0.001. *, **, *** indicate comparisons with respect to the control
group. #, ##, ### indicate comparisons with respect to the diabetic group.
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diabetic rats.The effects of punicalagin along with diabetes for
particular apoptotic proteins have been evaluated.
3.4.3. Bcl-2 and Bax
The analysis of the flow cytometry data revealed that the anti-
apoptotic protein Bcl-2 was significantly reduced, while the
apoptotic protein Bax was augmented in the hearts of STZ-
induced diabetic rats (Fig. 6a,b). Punicalagin treatment
considerably normalized the STZ-induced changes in the ex-
pression of these proteins.
3.4.4. Caspases-3, 8 and 9
In Fig. 7, the expression levels of caspases-3, 8 and 9 were sig-
nificantly up-regulated in the hearts of the STZ-induced diabetic
rats. Punicalagin administration significantly normalized these
apoptotic proteins (Figs. 6c,7a,b).
3.5. Comet assay
The changes in the levels of the comet parameters are
displayed in Fig. 8. The STZ-treated rats showed an
increase in the levels of all comet attributes, inclu-
ding percent DNA in tail, tail length and tail moment,
suggesting that DNA damage occurred in the diabetic
rats. Meanwhile, the treatment of diabetic rats with
punicalagin significantly repressed the increase in the comet
parameters.
Fig. 4 – Effects of streptozotocin (STZ) and punicalagin (PU) on the percentage of apoptosis in rats in different groups. Flow
cytometry results showing examples of the data generated by FACS are at the top of each histogram. The values are
expressed as the means ± SEM. (n = 7). *, # Significant at P < 0.05, **, ## significant at P < 0.01, and ***, ### significant at P < 0.001.
*, **, *** indicate comparisons with respect to the control group. #, ##, ### indicate comparisons with respect to the diabetic
group.
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3.6. Histological observations
The histological examination of heart sections from the control
and punicalagin-treated animals demonstrated the uniform size
and regular arrangement of the cardiac muscle fibers, with cen-
trally located round or oval nuclei. The heart sections of STZ-
diabetic rats showed a disorganized array of the myocardial
structure, myofibrillar discontinuation, myocyte degenera-
tion, and pyknotic nuclei. Punicalagin treatment of STZ-
induced diabetic rats reduced these changes in the STZ-
injected rat hearts and revealed markedly less disorganization
of the architecture of most of the cardiac muscle fibers, with
centrally located vesicular nuclei (Fig. 9).
4. Discussion
The actual prevention and management of diabetic cardio-
myopathy continues to be an essential health issue. To our
knowledge, this is the first study demonstrating that punicalagin
has cardioprotective effects in STZ-induced diabetes and that
punicalagin reduces the risk of diabetes-induced cardiac
apoptosis. Oxidative stress is a core player in the cardiac patho-
physiology of hyperglycemia-induced cardiac injury; therefore,
it is hypothesized that treatment with bioactive antioxidants
is a promising approach to block the pathological changes and
protect the heart function.
In the diabetic rats, the body weights were significantly de-
creased, which may be attributed to increased metabolism of
the muscle tissue, fats and proteins [32]. In punicalagin-
treated diabetic rats, the body weights were markedly
maintained within control levels, indicating a role of punicalagin
in protecting against muscle damage, possibly by influencing
disturbed muscle protein turnover and the subsequent loss of
muscle mass after diabetic induction.
Punicalagin treatment significantly lowered fasting serum
glucose, HbA1c and HOMA-IR levels and increased the insulin
level in STZ-treated rats at the end of the experimental period.
The mechanism underlying the glucose-lowering effect
Fig. 5 – Effects of streptozotocin (STZ) and punicalagin (PU) on the percentage of CD95 (a) and P53 (b) in rats in different
groups. Flow cytometry results showing examples of the data generated by FACS are at the side of each histogram. The
values are expressed as the means ± SEM. (n = 7). *, # Significant at P < 0.05, **, ## significant at P < 0.01, and ***, ### significant
at P < 0.001. *, **, *** indicate comparisons with respect to the control group. #, ##, ### indicate comparisons with respect to the
diabetic group.
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of punicalagin may be due to increased insulin release from
the protected and/or remaining β-cells, restored insulin sen-
sitivity [33], changes in the absorption of dietary carbohydrates
in the small intestine and facilitated utilization of glucose by
the peripheral tissues that is mediated by an insulin-dependent
glucose transporter [34].The present results are consistent with
findings from cell culture and animal studies as well as clini-
cal human research that pomegranates rich in punicalagin
exhibited anti-diabetic effect [12]. A pomegranate seed metha-
nol extract that is rich in punicalagin showed hypoglycemic
activity in STZ-induced diabetes and improved insulin sensi-
tivity in rodent animals [35].
It is well known that maintaining normal serum lipid levels
through nutrition programs is an effective approach to de-
crease the major risk of cardiovascular disease and related
disease complications [36]. In the current study, the total cho-
lesterol, LDL-cholesterol,VLDL-cholesterol and triglyceride levels
in the serumwere significantly reduced after diabetic rats were
treated with punicalagin, indicating its beneficial effect on the
lipid profile. In Zucker fatty diabetic rats, the pomegranate
extract improved abnormal cardiac lipid metabolism by
activating peroxisome proliferator-activated receptor-alpha
(PPAR-α), thereby decreasing the circulating lipid levels and in-
hibiting their cardiac uptake [37]. PPAR-α is a cardiac
transcription factor involved in myocardial energy produc-
tion via fatty acid uptake and oxidation.The augmented fatty
acid oxidation improves insulin sensitivity by reducing lipid
accumulation in the heart [38]. The beneficial effect of
punicalagin on the lipid profile in the present study explains
the clinical study in diabetic patients with hyperlipidemia
[16,39]. The authors claimed that pomegranate reduced cho-
lesterol absorption, increased cholesterol excretion in feces,
exerted positive effects on cholesterol metabolizing enzymes,
markedly decreased total and LDL-cholesterol and improved
the total/HDL and LDL/HDL-cholesterol ratios [16]. Moreover,
the pomegranate-mediated reduction of oxidized-LDL cellu-
lar uptake and cellular cholesterol biosynthesis was associated
with a significant reduction in cellular oxidative stress [40] [41].
In accord with these results, PPARγ modulation by punicalagin
resulted in reduced oxidative stress in macrophages in vitro [42].
Thus, punicalagin treatment reduces lipid risk factors, con-
firming its anti-hyperlipidemic effects in diabetic rats.
Fig. 6 – Effects of streptozotocin (STZ) and punicalagin (PU) on the percentage of Bcl-2 (a) and Bax (b) in rats in different
groups. Flow cytometry results showing examples of the data generated by FACS are at the side of each histogram. The
values are expressed as the means ± SEM. (n = 7). *, # Significant at P < 0.05, **, ## significant at P < 0.01, and ***, ### significant
at P < 0.001. *, **, *** indicate comparisons with respect to the control group. #, ##, ### indicate comparisons with respect to the
diabetic group.
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A number of publications have reported the involvement
of lipid peroxidation in the pathogenesis of diabetes-
induced cardiac injury. The increased levels of H2O2 and MDA
with decreased levels of SOD, CAT and GSH established ex-
cessive oxidative stress in STZ-induced diabetic rats. The
increase in oxidative stress in diabetic rats is a consequence
of higher ROS generation, which are produced by metabolic dis-
turbances [1,43]. Punicalagin treatment significantly decreased
the oxidative stress parameters, increased the GSH levels and
normalized the activities of antioxidant enzymes in the hearts
of STZ-treated rats, demonstrating the anti-peroxidation effect
of punicalagin. It is worth mentioning that punicalagin treat-
ment significantly augmented the GSH levels in the rat heart,
revealing its potential ability to improve the antioxidant mecha-
nisms in the heart. Similarly, there was a significant increase
in the GSH content in the heart of the pomegranate-treated
rats compared to the doxorubicin-treated group, indicating
an antioxidant effect against doxorubicin-induced oxidative
cardiotoxicity in rats [44].These results indicate that punicalagin
possesses potent antioxidant capacity that is responsible for
cardioprotection against oxidative stress.
Moreover, punicalagin administration significantly amelio-
rated the elevated levels of troponin T levels and LDH and CK-
MB activities toward normal levels, indicating that punicalagin
is an efficient cardioprotectant in diabetic conditions and can
protect cardiomyocyte membrane integrity. Histopathologi-
cal examination of the heart confirmed this finding and showed
that punicalagin effectively prevented STZ-induced cardiac
damage. The current data coincide with the ability of the
punicalagin-rich pomegranate to protect against I/R injury, doxo-
rubicin and isoproterenol-induced cardiotoxicity in rats, likely
because of its actions in enhancing oxygen free radical scav-
enging activity and decreasing lipid peroxidative damage
[10,44,45]. These results indicate that punicalagin can defend
the heart against oxidative stress and the associated pathol-
ogy and dysfunction.
The increase in ROS resulting from sustained hyperglyce-
mia can lead to myocardial inflammation, which is
characterized by the production of large number of cytokines
[46]. Previous studies reported that the levels of proinflammatory
cytokines and ROS were markedly increased and were asso-
ciated with impaired glucose tolerance [47,48].Therefore, it has
Fig. 7 – Effects of streptozotocin (STZ) and punicalagin (PU) on caspases 3 (a), 8 (b) and 9 (c) expressions in rat hearts in rats
in different groups. Flow cytometry data showing examples of the data generated by FACS are at the side of each
histogram. The values are expressed as the means ± SEM. (n = 7). *, # Significant at P < 0.05, **, ## significant at P < 0.01, and
***
, ###
significant at P < 0.001. *, **, *** indicate comparisons with respect to the control group. #, ##, ### indicate comparisons
with respect to the diabetic group.
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been hypothesized that punicalagin can modulate cellular ac-
tivity during inflammation due to its antioxidant properties.
The current study demonstrated that punicalagin attenuated
IL-1b, IL-6 and TNF-α in STZ-induced diabetes in rats. Several
recent experimental studies suggest anti-inflammatory effects
of pomegranate polyphenols in other settings that are char-
acterized by increased oxidative stress. It has been reported
that punicalagin treatment attenuated the elevation of TNF-
alpha, IL-6 and IL-1b after LPS-induced acute respiratory distress
syndrome in mice [49], in rat primary microglia [22], in cere-
bral I/R in rats [50] and in an in vitro model of human intestinal
epithelium [51]. These data suggest that punicalagin could be
an interesting nutritional source that contributes to prevent-
ing myocardial inflammation in diseases characterized by
excessive oxidative stress, such as diabetes.
To understand the mechanism underlying the
cardioprotective action of punicalagin on cardiac apoptosis in
diabetes, we investigated the involvement of the STZ-mediated
extrinsic and intrinsic apoptotic cell death pathway in cardiac
tissues. Flow cytometry analysis demonstrated that punicalagin
treatment ameliorated STZ-induced programmed cell death in
cardiac tissues by regulating pro-apoptotic proteins, such as
CD95; caspases-3, 8, and 9; Bax; and P53, and anti-apoptotic
proteins, such as Bcl-2.These results indicate a marked modu-
lation of both mitochondrial and death receptor apoptotic
pathways in the hearts of punicalagin-treated diabetic rats and
provide evidence that punicalagin has the ability to modu-
late apoptotic pathways in diabetes. Punicalagin significantly
decreased trophoblast death as shown by the reduced levels
of cleaved-PARP and LDH release [52]. Punicalagin-rich pome-
granate peel extract protected the liver and kidneys by
stimulating antioxidant activities and elevating the anti-
apoptotic protein Bcl-2 [53]. Punicalagin reduced cerebral
ischemia-reperfusion effects via attenuation of proinflammatory
cytokines, up-regulation of Bcl-2 and down-regulation of Bax
and caspase-3 [50]. In contrast to the induction of apoptosis
Fig. 8 – Effect of streptozotocin (STZ) and punicalagin (PU) on the percentage of DNA damage in hearts of rats in different
groups using the alkali comet assay that detects DNA single-strand breaks. (a) Percent of tail DNA, (b) tail length, and (c) tail
moment. The appearance of the microscopic images of representative comets for the different groups is shown. The values
are expressed as the means ± SEM. (n = 7). *, # Significant at P < 0.05, **, ## significant at P < 0.01, and ***, ### significant at
P < 0.001. *, **, *** indicate comparisons with respect to the control group. #, ##, ### indicate comparisons with respect to the
diabetic group.
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reported in cancer cells [54], punicalagin protects against heart
cell death in STZ-induced diabetes, reflecting the cell type-
specific nature of the responses to punicalagin.
In addition, STZ-induced cardiac apoptosis was also evident
from the DNA damage. A significant correlation between oxi-
dative DNA damage and hyperglycemia was previously reported
[55]. Punicalagin treatment protected cardiac tissue from STZ-
induced DNA damage, as evidenced by the inhibition of the
increase of comet parameters compared to the diabetic rats.
This implies that punicalagin prevented DNA strand breaks and
maintained its supercoiled loops in an appropriately firm status.
The precise mechanism is unidentified. However, this may be
attributed to the effective antioxidant capacity of punicalagin.
Therefore, punicalagin can decrease the DNA damage by scav-
enging the ROS in diabetic cases.
Significantly, the current results display, for the first time,
that punicalagin has biological activities in addition to being
an antioxidant in the diabetic heart. Punicalagin showed anti-
apoptotic effects and protected DNA. It can trigger a variety
of anti-apoptotic pathways due to its inherited antioxidant prop-
erty. Punicalagin treatment effectively down-regulates P53 and
up-regulates Bcl-2 and intracellular GSH levels in the STZ-
treated rats. P53 and its regulated genes can be activated by
hyperglycemia, leading to cardiomyocyte death [56]. It is re-
ported that P53 has the ability to induce apoptosis by an ROS-
dependent pathway [57,58]. In contrast, Bcl-2 exhibits an anti-
apoptotic and anti-necrotic influence via its antioxidant effect
on intracellular ROS [43,59]. Bcl-2 can decrease lipid peroxidation
by increasing cell resistance to ROS and blocking ROS produc-
tion [58]. Accordingly, it is suggested that the anti-apoptotic
effect of punicalagin may occur via down-regulating P53
induction and up-regulating Bcl-2, which is related to the en-
hanced GSH and antioxidant levels in the heart. It also seems
that punicalagin decreases apoptosis by blocking DNA damage
via the suppression of caspases and pro-inflammatory cytokines
that may be related to its anti-glycemic and anti-hyperlipidemic
actions.
In conclusion, the underlying mechanisms of punicalagin-
induced protection against diabetic cardiomyopathy are
pleiotropic and include anti-hyperglycemic, anti-hyperlipidemic,
antioxidant and anti-inflammatory activities. It can play an im-
portant role in the modulation of inflammatory and apoptotic
cell signaling in the diabetic heart.
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